罗格列酮对2型糖尿病心血管相关标志物的影响  

Effects of rosiglitazone on markers for cardiovascular disease in type 2 diabetes mellitus

作　　者：王涤非[1] 邱忠霞[1] 蒋丽娟[1] 张锦[2] 

机构地区：[1]中国医科大学附属第一医院老年病科,辽宁沈阳110001 [2]中国医科大学附属第一医院内分泌科,辽宁沈阳110001

出　　处：《中国医科大学学报》2006年第2期177-178,共2页Journal of China Medical University

基　　金：辽宁省教育厅高等学校科研基金资助项目(2004D196)

摘　　要：目的:观察2型糖尿病的一些心血管相关标志物水平变化及罗格列酮(RSG)对这些标志物的影响。方法:157例受试者分为正常对照组(NGT)、糖耐量低减组(IGT)、2型糖尿病未合并大血管病变组(DM1)及合并大血管病变组(DM2)。应用RSG(4 mg/d)治疗16周后,观察C反应蛋白(CRP)、I型血浆纤溶酶原活化抑制剂(PAI-1)、假性血友病因子(vWF)、基质金属蛋白酶-9(MMP-9)的水平变化。结果:治疗前从NGT、IGT、DM1到DM2组,CRP、PAI-1、vWF、MMP-9水平逐渐升高,CRP、PAI-1在各组间有显著差异(P<0.05);DM1、DM2组vWF和MMP-9与NGT、IGT组比较有显著差异(P<0.05);经RSG治疗后,IGT组、DM1组CRP水平明显下降(P<0.01),各组PAI-1下降(P<0.01),DM2组vWF和MMP-9下降(P<0.05)。结论:RSG不同程度降低心血管相关标志物水平,对IGT和2型糖尿病心血管具有保护作用。Objective： To investigate the levels of markers for cardiovascular disease in type 2 diabetes mellitus and the effect of rosiglitazone （RSG） on these markers. Methods：This study included 43 healthy subjects （NGT group）, 40 patients with impaired glucose tolerance （ IGT group）, and 74 patients with type 2 diabetes mellitus （T2DM）. The patients with T2DM were further divided into T2DM without （DM, group, 32 patients） and with （DM2 group, 42 patients） macrovaseular complication. The markers for cardiovascular disease including serum C-reactive protein （ CRP）, plasminogen activator inhibitor type-1 （ PAI-1 ）, yon WiUebrand factor （vWF）, and serum matrix metalloproteinase-9 （MMP-9） were detected 16 weeks after the patients being treated with RSG （4 Mg/d）. Results：The levels of CRP, PAI-1, vWF and MMP-9 in NGT, IGT, DM1, and DM2 groups gradually increased in sequence. There were significant differences in the levels of CRP and PAI-1 between any 2 of these 4 groups （ P 〈 0.05 ）. The levels of vWF and MMP-9 in DM1 and DM2 groups were significantly higher than those in NGT and IGT groups. The level of CRP in IGT and DMI groups, the level of PAI-1 in each group, and the levels of vWF and MMP-9 in DM2 group after the admininstration of RSG were significantly lower than those before the administration （ P 〈 0.01 ）. Conclusion：Some markers for cardiovascular diseases significantly increase in patients with IGT and T2DM, and RSG could effectively inhibit the increase of these markers and thus have a protective effect on macrovascular diseases.

关 键 词：罗格列酮 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]